BSD Medical Corporation Announces Investor & Analyst Conference Call

  BSD Medical Corporation Announces Investor & Analyst Conference Call

Live Conference Call and Webcast Scheduled for Wednesday, March 6 at 2:00 p.m.
             Eastern Time/12:00 p.m. Mountain Time; RSVP Required

Business Wire

SALT LAKE CITY -- February 20, 2013

BSD Medical Corporation (NASDAQ: BSDM) (Company or BSD), a leading provider of
medical systems that utilize heat therapy to treat cancer, today announced
that it will host an Investor & Analyst Update Call and live webcast on
Wednesday, March 6, 2013, at 2:00 p.m. Eastern time/12:00 p.m. Mountain time.
The call will be hosted by Harold Wolcott, President, and William Barth, CFO.

Individuals interested in participating in the conference call may do so by
visiting the Investor Relations section of the Company's website at or by dialing 800-762-8779 from the United States, or
480-629-9645 from outside the United States, and entering conference ID
4602120. We request that you RSVP to the conference call by emailing before 4:00 p.m. Eastern time on Monday, March 4, 2013.

A telephone replay will be available through March 13, 2013, by dialing
800-406-7325 from the United States, or 303-590-3030 from outside the United
States, and entering conference ID 4602120. A webcast replay will be available
for 90 days.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems
to treat cancer and benign diseases using heat therapy, which is delivered
using focused radiofrequency (RF) and microwave energy. BSD’s product lines
include both hyperthermia and ablation treatment systems. BSD’s hyperthermia
cancer treatment systems, which have been in use for several years in the
United States, Europe and Asia, are used to treat certain tumors with heat
(hyperthermia) while increasing the effectiveness of other therapies such as
radiation therapy. BSD’s microwave ablation system has been developed as a
stand-alone therapy to employ precision-guided microwave energy to ablate
(destroy) soft tissue. The Company has developed extensive intellectual
property, multiple products in the market and established distribution in the
United States, Europe and Asia. Certain of the Company’s products have
received regulatory approvals and clearances in the United States, Europe and
China. For further information visit BSD Medical's website at

Statements contained in this press release that are not historical facts are
forward-looking statements, as defined in the Private Securities Litigation
Reform Act of 1995. All forward-looking statements are subject to risks and
uncertainties detailed in the Company's filings with the Securities and
Exchange Commission. These forward-looking statements speak only as of the
date on which such statements are made, and the Company undertakes no
obligation to update such statements to reflect events or circumstances
arising after such date.


BSD Medical Corporation
William (Bill) S. Barth, 801-972-5555
Financial Profiles
Tricia Ross, 916-939-7285
Press spacebar to pause and continue. Press esc to stop.